<DOC>
	<DOCNO>NCT02556255</DOCNO>
	<brief_summary>The aim study assess safety efficacy use Eximo 's CathiTM hybrid catheter subject affect Peripheral Artery Disease ( PAD ) low extremity artery .</brief_summary>
	<brief_title>Safety Effectiveness Study Eximo 's CathiTM Atherectomy Device PAD Treatment</brief_title>
	<detailed_description>This prospective , single-arm , multi-center , international , open-label , non-randomized clinical study . All enrolled subject undergo atherectomy procedure , CathiTM catheter use perform atherectomy target lesion , follow adjunctive therapy ( balloon and/or stent etc. ) . The procedure do accord standard hospital procedure atherectomy . The step operation operate CathiTM device routinely use practice do accord local practice hospital . For post-atherectomy stage , adjunctive therapy procedure , approve device may use ( balloon and/or stent etc. ) . Subjects follow 12 month procedure .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Subject ≥ 18 year old . 2 . Subject candidate endovascular intervention peripheral artery disease low extremity . 3 . Documented symptomatic atherosclerotic peripheral artery disease Rutherford Classification 24 . 4 . Reference vessel lumen diameter proximal target lesion estimate &gt; 150 % outer diameter CathiTM , base CT Angiogram . 5 . Subject infrainguinal target lesion ( ) stenosis ( estimate ≥70 % base CT angiogram ) , restenosis , instent restenosis occlusion . 6 . The target lesion blood flow diameter estimate least 0.5 mm small Eximo catheter 's outer diameter base CT Angiogram . 7 . At least one patent tibial runoff vessel baseline . 8 . Subject capable willing comply , present , followup clinic visit least 30 day visit , intention arrive 6 month 12 month followup visit . 9 . Subject undergone standard care routine test procedure like PAD intervention , include WBC profile , coagulation status kidney function find suitable . 10 . Subject able willing sign write informed consent form ( ICF ) . Intraoperative inclusion criterion ( fluoroscopy angiogram ) : 1 . Reference vessel lumen diameter proximal target lesion &gt; 150 % outer diameter CathiTM . 2 . The target lesion blood flow diameter least 0.5 mm small Eximo catheter 's outer diameter . 3 . Target lesion crossed guidewire . 1 . Target lesion inguinal level artery . 2 . Target lesion length &gt; 25 cm . 3 . Rutherford Class &lt; 2 &gt; 4 4 . Severe calcification target lesion 5 . Target lesion thrombus embolic protection device intend use . 6 . Target lesion stenosis &lt; 70 % 7 . Reference vessel lumen diameter proximal target lesion estimate ≤150 % outer diameter CathiTM base CT Angiogram . 8 . Endovascular surgical procedure perform index limb less equal 30 day prior index procedure . 9 . Planned endovascular surgical procedure 30 day index procedure . 10 . Intent use atherectomy device procedure . 11 . Lesion contralateral limb require intervention index procedure within 30 day index procedure . 12 . Subjects active infection whether currently treat . 13 . Evidence history intracranial gastrointestinal bleeding , intracranial aneurysm , myocardial infarction stroke within past 2 month . 14 . Evidence history aneurysmal target vessel within past 2 month . 15 . History heparininduced thrombocytopenia ( HIT ) . 16 . Any clinical and/or angiographic complication attribute use another device prior study procedure . 17 . Any thrombolytic therapy within 2 week index procedure . 18 . History severe trauma , fracture , major surgery biopsy parenchymal organ within past 14 day . 19 . Known allergy contrast agent medication use perform endovascular intervention adequately pretreated . 20 . Subjects antiplatelet , anticoagulant , thrombolytic therapy contraindicate . 21 . Serious illness may affect subject compliance protocol . 22 . Participating clinical study may interfere study 's primary secondary endpoint . 23 . Any issue judgment investigator , may affect result study . 24 . Subject pregnant planning become pregnant study period . Intraoperative exclusion criterion ( fluoroscopy angiogram ) : 1 . Total occlusion Target lesion cross GW . 2 . Reference vessel lumen diameter proximal target lesion ≤150 % outer diameter CathiTM . 3 . An embolic protection device use lesion make thrombus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>PAD</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Peripheral Vascular Diseases</keyword>
	<keyword>PVD</keyword>
</DOC>